Delivery Order SPE2DB22D3301-SPE2DB26FX3ZE
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,846.97 to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Vyndamax 61 mg capsule unit dose packages (30-count). This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 29, 2025, with performance to be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting open...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Vyndamax 61 mg capsule unit dose packages (30-count). This order, valued at $13,846.97 with a firm fixed price structure, represents a non-competitive, non-set-aside procurement issued under a delivery order contract type and is scheduled for completion by August 18, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's facility in Conshohocken,...
- The Defense Logistics Agency awarded a $27,693.94 delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Vyndamax 61 mg capsules in unit dose packaging (30-count). This competitively awarded, firm fixed-price contract is scheduled for completion by August 19, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order carries no set-aside designation and represents a child contract under...
- The Defense Logistics Agency awarded a $87.6K delivery order to AmerisourceBergen Drug Corp on October 27, 2025, for the supply of Vyndamax 61 mg capsule unit dose packages (30-count). The contract employs firm fixed pricing and carries an ultimate completion date of November 18, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location. This delivery order was competitively awarded with no set-aside designation, reflecting...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Vyndamax 61 mg capsule unit dose packages (30-count). This competitively awarded, non-set-aside contract carries a ceiling value of $13,846.97 and has a firm fixed price structure with an ultimate completion date of September 18, 2025. The order will be fulfilled from AmerisourceBergen's operations in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a $41,540.91 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Vyndamax 61 mg capsules in unit dose packages of 30 units. This non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical will be delivered to...
- The Defense Logistics Agency (DLA) awarded a $14,592.57 delivery order to AmerisourceBergen Drug Corp on October 27, 2025, for the supply of Vyndamax 61 mg capsules in unit dose packaging (30-count). This competitively awarded, firm fixed-price contract is scheduled for completion by November 18, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a non-set-aside procurement, this order was open to competition and reflects the agency's...
- The Defense Logistics Agency awarded a $41,541 delivery order to AmerisourceBergen Drug Corp on October 30, 2025, for the supply of Vyndamax 61 mg capsule unit dose packages in quantities of 30. This is a firm fixed-price delivery order with no set-aside designation, issued under full and open competition. The contract is scheduled for completion by November 21, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a $55,387.88 delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Vyndamax 61 mg capsule unit dose packs (30-count). This is a firm fixed-price, competitively awarded contract with an ultimate completion date of October 20, 2025. The contract was performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a leading pharmaceutical distributor...
- The Defense Logistics Agency awarded a $14,592.57 delivery order to AmerisourceBergen Drug Corp on October 30, 2025, for the supply of Vyndamax 61 mg capsule unit dose packages (30-count). This competitively awarded, firm fixed-price delivery order is set to be completed by November 21, 2025, and will be performed at the contractor's Conshohocken, Pennsylvania facility. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- SPE2DB22D3301Indefinite Delivery Contract
- SPE2DB22D3301-SPE2DB26FX3ZEDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $83,081.82 to AmerisourceBergen Drug Corp on October 28, 2025, for the supply of Vyndamax 61 mg capsule unit dose packages (30-count). This competitively awarded, firm fixed-price contract carries an ultimate completion date of November 19, 2025, and represents a child order under a larger contract vehicle. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is executed under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The IDC functions as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of medications, vaccines, and medical supplies to support military healthcare programs worldwide. AmerisourceBergen is one of the primary pharmaceutical distributors supporting federal medical procurement needs, with demonstrated capability to fulfill competitive awards across multiple therapeutic domains including specialty medications and brand-name pharmaceuticals for military and veteran healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $83.1k | 10/28/25 |